Document Detail

MedLine Citation:
PMID:  20065632     Owner:  NLM     Status:  MEDLINE    
Motavizumab (MEDI-524, Numax) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.
Oya Cingoz
Publication Detail:
Type:  Journal Article; Review     Date:  2009-09-10
Journal Detail:
Title:  mAbs     Volume:  1     ISSN:  1942-0870     ISO Abbreviation:  MAbs     Publication Date:    2009 Sep-Oct
Date Detail:
Created Date:  2010-01-12     Completed Date:  2010-04-05     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  101479829     Medline TA:  MAbs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  439-42     Citation Subset:  IM    
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal* / administration & dosage,  adverse effects,  immunology,  therapeutic use
Antibodies, Monoclonal, Humanized
Child, Preschool
Clinical Trials as Topic
Infant, Newborn
Respiratory Syncytial Virus Infections / drug therapy*,  immunology,  prevention & control*
Respiratory Syncytial Virus, Human / immunology*
Treatment Outcome
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/motavizumab
Erratum In:
MAbs. 2010 Sep-Oct;2(5):591

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Association between a history of falls and the ability to multi-task in community-dwelling older peo...
Next Document:  Tocilizumab.